Bryant England, MD
Internal Medicine · Omaha, NENPI 1235490384
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,448 of the $7,570 with a category attached, or 98.4%. Boehringer Ingelheim accounts for 98.5% of it on its own, with 2 other manufacturers making up the rest. 2025 is the largest year on record at $3,840, more than ten times the $13 reported in 2019. Among internal medicine clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 7 payments — averaging $1081.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$7K
- Johnson & Johnson$55
- AstraZeneca$55
Across 21 payments — averaging $30,001 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$388K
- Boehringer Ingelheim$242K
- Pfizer$330
What the payments were for
- Consulting fees$7,44898%
- Food & beverage$681%
- Education$551%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 5 | $7,460 |
| Johnson & Johnson | 1 | $55 |
| AstraZeneca | 1 | $55 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$2,880
How this compares
$7,570 in reported general payments places this provider in the 95th percentile of 570 internal medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 13 | $91,423 |
| Actemra ActpenTocilizumab | 12 | $24,936 |
| MethotrexateMethotrexate Sodium | 17 | $1,153 |
| Azathioprine | 22 | $768 |
| Allopurinol | 37 | $471 |
| Hydroxychloroquine Sulfate | 16 | $453 |
| Prednisone | 24 | $245 |
| Sulfasalazine DrSulfasalazine | 11 | $232 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Omaha
- Brian BoerOmaha$142K
- Adam BurdorfOmaha$29K
- David SharpOmaha$26K
- David ShinOmaha$26K
- Nikhil JaganOmaha$20K
- Clayton SchroederOmaha$14K
- Ali NayfehOmaha$12K
- Kirtibala GuptaOmaha$12K
- Chad VokounOmaha$11K
- Joel MichalskiOmaha$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.